Deals
Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B
Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…
Deals — Page 7
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Counted $700M in Benko Losses, Julius Baer Now Counts CFO Days
Julius Baer has been counting losses for two years.
Deals
Blackstone Files $2B IPO for AI Data Center Buyer
Blackstone filed confidential IPO paperwork with U.S. regulators to raise $2 billion for a dedicated acquisition vehicle targeting data centers, Bloomberg…
Deals
Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement
Novo Nordisk is losing a key obesity figure.
Deals
Shionogi Wins $119M BARDA Contract for Fetroja
Shionogi has been awarded a $119 million contract from BARDA for Fetroja, a direct government commitment to the drugmaker's drug.
Deals
Closed Above Target, Jeito Capital Fund II Hits €1.6B AUM
Jeito Capital closed Jeito II at more than €1bn, lifting the firm's total AUM to €1.6bn.
Deals
BARDA Cut $482m Shionogi Deal for US Antibiotic Capacity
BARDA paid $482m to get Fetroja made on US soil.
Deals
Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal
Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…
Deals
Polygon Targets $50M-$100M Equity Round as Token Sheds 90%
Polygon Labs seeks $50M-$100M in equity to build its Open Money Stack stablecoin platform, a bet on payments as its native token shed 90% of its value.
Deals
Steve Ubl Steps Down as PhRMA Chief Amid Drug Pricing Battle
PhRMA leader Steve Ubl plans to step down at a pivotal moment for pharma's most powerful DC trade group, Endpoints News reports.
Deals
Gilead Spends $14.77B on Three Deals, Then Hits Pause
Gilead bought Arcellx, Ouro, and Tubulis for $14.77B in under ten weeks. CFO says further big deals are unlikely this year, but the door stays open.
Deals
KreditBee Hits $1.5B Valuation on $280M Round, Joins Unicorn Club
KreditBee joins India's unicorn club as investors bet on the country's underserved lending market.
Deals
Merck Cut Terns Bid by $1B After Leukemia Data Missed
Merck cut its Terns offer from $7.7B to $6.7B after Phase 1 leukemia data disappointed. The rival bidder walked entirely.
Deals
Whoop Closes $575M Series G as Health Tech Q1 Doubles Down on AI
Whoop's $575M Series G tops a Q1 health tech funding wave built on AI clinical workflow bets, with no post-money valuation disclosed yet.
Deals
Lilly Bets on Orexins, Tirzepatide Playbook Repeats
Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.
Deals
Digital Health Posts $4B Q1 Record as 12 Deals Take 59%
Digital health hit $4B in Q1 2026, up $1B year-over-year, but 12 mega-deals claimed 59% of all capital as total deal count fell to 110.
Deals
Apnimed Locks $150M Credit Line for AD109 Sleep Apnea Launch
Apnimed secured up to $150M from HCRx to launch AD109, with only $50M unconditional and the rest tied to FDA approval and a sales milestone.
Deals
Gilead Pays $3.15B for Tubulis in Third ADC Bet of 2026
Gilead's $3.15B upfront buy of Tubulis adds a 59%-ORR NaPi2b ADC to its pipeline — its third acquisition of 2026, totaling over $12B spent.
Deals
Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race
Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.
deals
Deals
Takeda Files WARN for 634 US Cuts, 247 of Them at Cambridge HQ
Takeda filed a WARN notice to cut 634 US jobs, with 247 hitting its Cambridge headquarters — the largest concentration in the restructuring.
